Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRKNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$81.21+0.3%$79.20$73.31▼$129.93$204.03B0.3913.24 million shs2.44 million shsSMMTSummit Therapeutics$23.31-5.0%$22.75$7.23▼$36.91$17.28B-1.013.71 million shs1.32 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.0.00%+2.58%+2.56%-0.17%-35.97%SMMTSummit Therapeutics0.00%+18.18%+18.24%+40.56%+236.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRKMerck & Co., Inc.4.9961 of 5 stars3.23.05.04.23.02.53.8SMMTSummit Therapeutics2.5031 of 5 stars4.41.00.00.02.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.43Hold$109.1934.45% UpsideSMMTSummit Therapeutics 2.79Moderate Buy$34.6748.70% UpsideCurrent Analyst Ratings BreakdownLatest SMMT and MRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.007/1/2025SMMTSummit TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/11/2025SMMTSummit TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/11/2025SMMTSummit TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$12.006/2/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.005/20/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Cautious5/14/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$115.00 ➝ $84.005/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.004/28/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$64.17B3.18$9.50 per share8.55$18.33 per share4.43SMMTSummit Therapeutics$700K24,734.09N/AN/A$0.53 per share43.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$17.12B$6.8711.838.200.8427.27%43.23%17.11%7/29/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)Latest SMMT and MRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03N/AN/AN/A$15.92 billionN/A5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A4/24/2025Q1 2025MRKMerck & Co., Inc.$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.243.99%N/A47.16%14 YearsSMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest SMMT and MRK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/27/2025MRKMerck & Co., Inc.quarterly$0.814.18%6/16/20256/16/20257/8/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.0.691.411.16SMMTSummit TherapeuticsN/A10.6310.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.09%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.75,0002.51 billion2.51 billionOptionableSMMTSummit Therapeutics110742.67 million112.14 millionOptionableSMMT and MRK HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's Why1 hour ago | marketbeat.comSMMT Stock Gains on Rumored Licensing Talks With AstraZeneca2 hours ago | zacks.comSummit Therapeutics Inc. (SMMT) - Yahoo FinanceJuly 5 at 7:37 AM | finance.yahoo.comStock Traders Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)July 5 at 2:11 AM | americanbankingnews.com2 Soaring Stocks With More Upside Potential to Buy and HoldJuly 4 at 8:15 AM | fool.comAstraZeneca in talks with Summit for over $15 billion license dealJuly 4 at 6:48 AM | thepharmaletter.comTSummit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reportsJuly 3, 2025 | msn.comSummit Therapeutics Shares Climb Amid Rumored $15B Deal Talks with AstraZenecaJuly 3, 2025 | msn.comSummit said to be in talks with Astra to license potential rival for Merck’s KeytrudaJuly 3, 2025 | msn.comWhy Summit Therapeutics Stock Soared 8% Higher TodayJuly 3, 2025 | fool.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.3% - Should You Sell?July 3, 2025 | marketbeat.comSummit Therapeutics Target of Unusually High Options Trading (NASDAQ:SMMT)July 3, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at UBS GroupJuly 3, 2025 | americanbankingnews.comWall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeJuly 2, 2025 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 2, 2025 | prnewswire.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives $35.09 Consensus PT from BrokeragesJuly 2, 2025 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from HC WainwrightJuly 2, 2025 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Summit Therapeutics (NASDAQ:SMMT)July 1, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at UBS GroupJuly 1, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Rating Increased to Hold at Wall Street ZenJune 30, 2025 | americanbankingnews.comSummit Therapeutics PLC (NASDAQ:SMMT) Stock Position Lifted by Sovran Advisors LLCJune 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMMT and MRK Company DescriptionsMerck & Co., Inc. NYSE:MRK$81.21 +0.28 (+0.34%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Summit Therapeutics NASDAQ:SMMT$23.31 -1.24 (-5.04%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
